{"id":822515,"date":"2026-06-30T03:23:02","date_gmt":"2026-06-30T03:23:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=822515"},"modified":"2026-06-30T03:23:02","modified_gmt":"2026-06-30T03:23:02","slug":"clostridium-difficile-infections-market-forecast-signals-robust-industry-growth-through-2034-delveinsight-seres-therapeutics-nestl-health-science-adiso-therapeutics-deinove-acurx-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/clostridium-difficile-infections-market-forecast-signals-robust-industry-growth-through-2034-delveinsight-seres-therapeutics-nestl-health-science-adiso-therapeutics-deinove-acurx-pharma_822515.html","title":{"rendered":"Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 \u2013 DelveInsight | Seres Therapeutics, Nestl\u00e9 Health Science, Adiso Therapeutics, Deinove, Acurx Pharma"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1782498911.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 &ndash; DelveInsight | Seres Therapeutics, Nestl&eacute; Health Science, Adiso Therapeutics, Deinove, Acurx Pharma\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1782498911.jpg\" alt=\"Clostridium Difficile Infections Market Forecast Signals Robust Industry Growth Through 2034 &ndash; DelveInsight | Seres Therapeutics, Nestl&eacute; Health Science, Adiso Therapeutics, Deinove, Acurx Pharma\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Clostridium Difficile Infections Companies in the market include- Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Clostridium Difficile Infections market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Clostridium Difficile Infections pipeline products will significantly revolutionize the Clostridium Difficile Infections market dynamics.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s <strong>&#8220;Clostridium Difficile Infections Market Insights, Epidemiology, and Market Forecast-2034&#8221;<\/strong> report provides a thorough understanding of Clostridium Difficile Infections, including historical and projected epidemiology, as well as market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Clostridium Difficile Infections market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2020 to 2034. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Clostridium Difficile Infections market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Clostridium Difficile Infections Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Clostridium Difficile Infections Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Clostridioides difficile infection market size across the seven major markets (7MM) was valued at approximately <strong>USD 551 million in 2025<\/strong> and is projected to reach <strong>USD 1,715 million by 2034,<\/strong> expanding at a<strong> CAGR of 13.5%<\/strong> across the United States, EU4, the UK, and Japan.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2026, Elaris<\/strong> has strengthened its infectious disease portfolio by acquiring a key vaccine asset from Matrivax, aimed at advancing its Clostridioides difficile (C. diff) vaccine program beyond conventional toxin-focused strategies. While most investigational C. diff vaccines are designed to neutralize toxins A and B to reduce disease symptoms, they do not address bacterial colonization or transmission. The acquired technology utilizes a proprietary surface-polysaccharide conjugate platform that targets the bacterial cell surface, offering a complementary mechanism of action. By integrating toxin neutralization with colonization prevention, Elaris is developing a differentiated dual-action vaccine intended to reduce both initial infections and disease recurrence. This acquisition further strengthens the company&#8217;s pipeline and supports the development of next-generation preventive solutions for healthcare-associated infections.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, AstraZeneca<\/strong> announced results from a Phase IIb randomized, double-blind, placebo-controlled study assessing the efficacy and safety of AZD5148 for preventing recurrence of Clostridioides difficile Infection in individuals aged 18 years and older.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, Vedanta Biosciences<\/strong> announced results from a randomized, double-blind, placebo-controlled Phase III clinical trial evaluating VE303 for the prevention of recurrent Clostridioides difficile Infection.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, Acurx Pharmaceuticals a<\/strong>nnounced results from the Phase II IBZ-PATHFINDER study, an interventional, open-label, single-arm clinical trial evaluating oral Ibezapolstat for the treatment and reduction of recurrent Clostridioides difficile Infection in patients experiencing multiple recurrent infections.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2026, Lumen Bioscience<\/strong> announced results from a Phase II randomized, double-blind, placebo-controlled clinical trial evaluating LMN-201 for the prevention of recurrent Clostridioides difficile Infection.<\/p>\n<\/li>\n<li>\n<p><strong>In November 2025, The U.S. Food and Drug Administration<\/strong> has cleared the investigational new drug application submitted by Immuron Limited for IMM-529 (IND 032095), permitting the initiation of a Phase II clinical trial in adults with Clostridioides difficile Infection. The company intends to begin the study in the first half of 2026. The multicenter trial, to be conducted in Australia, will enroll up to 60 participants experiencing either a first episode or recurrent infection. Designed as a randomized, double-blind, placebo-controlled study, participants will be assigned in a 2:1 ratio to receive IMM-529 alongside standard of care or placebo with standard treatment. The main goal of the study is to evaluate safety and tolerability, while secondary efficacy measures will assess mortality, symptom improvement, and recurrence rates.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2025, Lumen Bioscience<\/strong> shared top-line findings from the sentinel cohort of its RePreve Clinical Trial assessing LMN-201 for Clostridioides difficile infection (CDI). LMN-201 is an oral biologic combination therapy, provided in capsule form, designed to be administered alongside and after antibiotics to enhance clinical outcomes in CDI. The therapy is developed using Lumen&rsquo;s proprietary spirulina-based GMP manufacturing platform.<\/p>\n<\/li>\n<li>\n<p><strong>In February 2025, Microbiotica<\/strong> presented new insights into the mechanism of action of MB097 at the American Association for Cancer Research (AACR) Immuno-Oncology conference held in Los Angeles from February 23-26. MB097, a live biotherapeutic product (LBP), is being developed to complement immuno-oncology treatments, including MSD&rsquo;s anti-PD-1 therapy, KEYTRUDA (pembrolizumab).<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, Vedanta Biosciences,<\/strong> a late clinical-stage biotechnology company focused on developing defined bacterial consortia as oral therapies for gastrointestinal disorders, announced the publication of further findings from its Phase II CONSORTIUM trial of its lead candidate, VE303, aimed at preventing recurrent *Clostridioides difficile* infection (rCDI). The latest analyses were published this month in Nature Medicine and are accessible online<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, MaaT Pharma<\/strong> revealed the topline results from ARES, a key European Phase 3 multicenter trial. This single-arm, open-label study assessed the efficacy and safety of MaaT013 in patients with acute gastrointestinal Graft-versus-Host Disease (GI-aGvHD). The trial focused on third-line treatment for patients who were steroid-resistant and either refractory or intolerant to ruxolitinib.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2025, PureTech Health plc<\/strong> announced that Vedanta Biosciences, a company it founded, has published new results from the Phase 2 CONSORTIUM study on VE303, its leading candidate under evaluation for preventing recurrent Clostridioides difficile infection (rCDI).<\/p>\n<\/li>\n<li>\n<p>The total market size of Clostridioides Difficile Infection in the 7MM is nearly USD ~ 500 million in 2024 and is projected to grow during the forecast period (2025&ndash;2034).<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&rsquo;s estimates, the largest market size of Clostridioides Difficile Infection is captured by the US in 2024.<\/p>\n<\/li>\n<li>\n<p>In EU4 and the UK, Germany has the maximum market share, followed by France in 2024 while Spain had the lowest market share.<\/p>\n<\/li>\n<li>\n<p>The market size of Clostridioides Difficile Infection in Japan was USD ~9 million in 2024, which is expected to rise during the forecast period (2025&ndash;2034).<\/p>\n<\/li>\n<li>\n<p>The total number of incident cases of Clostridioides Difficile Infection in the 7MM was around 6,11,000 in 2024.<\/p>\n<\/li>\n<li>\n<p>In the 7MM, the highest incident cases of Clostridioides Difficile Infection were in the US, accounting for nearly 3,80,000 cases in 2024. These cases are anticipated to increase in the upcoming years.<\/p>\n<\/li>\n<li>\n<p>In 2024, the Clostridioides Difficile Infection incidence cases by type in the US were identified to be HA-Clostridioides Difficile Infection at ~45% and CA-Clostridioides Difficile Infection at ~55% share.<\/p>\n<\/li>\n<li>\n<p>There are significant gaps in the epidemiological data of Clostridioides Difficile Infection in Japan, and Clostridioides Difficile Infection is frequently underdiagnosed in the country despite its clinical relevance.<\/p>\n<\/li>\n<li>\n<p>In the United States, the incident cases of Clostridioides Difficile Infection by gender were higher among females compared to males in 2024.<\/p>\n<\/li>\n<li>\n<p>In the 7MM in 2024, approximately 464,000 Clostridioides Difficile Infection cases were classified as mild to moderate, while around 147,000 cases were categorized as severe.<\/p>\n<\/li>\n<li>\n<p>In 2024, the incidence cases of Clostridioides Difficile Infection in the UK were estimated at approximately 1,000 in<\/p>\n<\/li>\n<li>\n<p><strong>Key Clostridium Difficile Infections Companies:<\/strong> Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Clostridium Difficile Infections Therapies:<\/strong> ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others<\/p>\n<\/li>\n<li>\n<p>The Clostridium Difficile Infections epidemiology based on gender analyzed that more incident cases of Clostridium Difficile Infections were seen in females<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Clostridium difficile infections (CDI) are caused by the bacterium Clostridium difficile (often referred to as C. diff). This infection primarily affects the colon and can lead to symptoms ranging from mild diarrhea to severe and life-threatening inflammation of the colon (colitis).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Clostridium Difficile Infections Market Report &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Market <\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Clostridium Difficile Infections market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section offers an in-depth look at the historical, current, and projected epidemiology trends across the seven major countries (7MM) from 2020 to 2034. By examining various studies and expert opinions, it identifies the factors driving present and future trends. This section also includes a comprehensive analysis of the diagnosed patient population and anticipated future patterns.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Clostridium Difficile Infections market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalence of Clostridium Difficile Infections<\/p>\n<\/li>\n<li>\n<p>Prevalent Cases of Clostridium Difficile Infections by severity<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalence of Clostridium Difficile Infections<\/p>\n<\/li>\n<li>\n<p>Diagnosed Cases of Episodic and Chronic Clostridium Difficile Infections<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Clostridium Difficile Infections epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Clostridium Difficile Infections Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Clostridium Difficile Infections market or expected to get launched during the study period. The analysis covers Clostridium Difficile Infections market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Clostridium Difficile Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>DIFICID\/DIFICLIR\/DAFCLIR (fidaxomicin):<\/strong> Merck &amp; Co.\/Tillotts Pharma\/Astellas Pharma<\/p>\n<\/li>\n<li>\n<p><strong>VOWST:<\/strong> Seres Therapeutics\/Nestl&eacute; Health Science<\/p>\n<\/li>\n<li>\n<p><strong>Ibezapolstat:<\/strong> Acurx Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>MBK-01:<\/strong> Mikrobiomik<\/p>\n<\/li>\n<li>\n<p><strong>ADS024:<\/strong> Adiso Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>DNV3837:<\/strong> Deinove<\/p>\n<\/li>\n<li>\n<p><strong>Ibezapolstat:<\/strong> Acurx Pharmaceuticals, Inc<\/p>\n<\/li>\n<li>\n<p><strong>LMN-201:<\/strong>Lumen Bioscience, Inc<\/p>\n<\/li>\n<li>\n<p><strong>Ridinilazole:<\/strong> Summit Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>CP101:<\/strong> Finch Therapeutics Group<\/p>\n<\/li>\n<li>\n<p><strong>SER 109:<\/strong> Seres Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>VE303:<\/strong> Vedanta Biosciences<\/p>\n<\/li>\n<li>\n<p><strong>MGB-BP-3:<\/strong> MGB Biopharma<\/p>\n<\/li>\n<li>\n<p><strong>CRS3123:<\/strong> Replidyne<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Clostridium Difficile Infections treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Clostridium Difficile Infections Medications<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>New and emerging technologies are providing unprecedented possibilities for understanding and intervening in clostridium difficile infections management.<\/p>\n<\/li>\n<li>\n<p>Rising demand for antibiotics since antibiotics are the only treatment for this disease.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Clostridium Difficile Infections Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>There is an unmet need for a medication that restores the microbiota and interrupts the cycle of recurrence early is desperately needed. So any company that can come up with such a mechanism might get first mover advantages<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Clostridium Difficile Infections Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2020&ndash;2034<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Clostridium Difficile Infections Companies:<\/strong> Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Clostridium Difficile Infections Therapies:<\/strong> ADS024, DNV3837, Ibezapolstat, LMN-201, Ridinilazole, CP101, SER 109, VE303, MGB-BP-3, CRS3123, and others<\/p>\n<\/li>\n<li>\n<p><strong>Clostridium Difficile Infections Therapeutic Assessment:<\/strong> Clostridium Difficile Infections current marketed and Clostridium Difficile Infections emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Clostridium Difficile Infections Market Dynamics: <\/strong>Clostridium Difficile Infections market drivers and Clostridium Difficile Infections market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis: <\/strong>SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Clostridium Difficile Infections Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Clostridium Difficile Infections Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Clostridium Difficile Infections market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/clostridium-difficile-infections-clostridium-difficile-associated-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Clostridium Difficile Infections Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Clostridium Difficile Infections Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Clostridium Difficile Infections<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Clostridium Difficile Infections<\/p>\n<p style=\"text-align: justify;\">4. Clostridium Difficile Infections Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Clostridium Difficile Infections Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Clostridium Difficile Infections Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Clostridium Difficile Infections Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Clostridium Difficile Infections<\/p>\n<p style=\"text-align: justify;\">9. Clostridium Difficile Infections Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Clostridium Difficile Infections Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Clostridium Difficile Infections Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Clostridium Difficile Infections Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Clostridium Difficile Infections Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify;\">14. Clostridium Difficile Infections Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Clostridium Difficile Infections Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Clostridium Difficile Infections Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Clostridium Difficile Infections Appendix<\/p>\n<p style=\"text-align: justify;\">18. Clostridium Difficile Infections Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=clostridium-difficile-infections-market-forecast-signals-robust-industry-growth-through-2034-delveinsight-seres-therapeutics-nestl-health-science-adiso-therapeutics-deinove-acurx-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=clostridium-difficile-infections-market-forecast-signals-robust-industry-growth-through-2034-delveinsight-seres-therapeutics-nestl-health-science-adiso-therapeutics-deinove-acurx-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Clostridium Difficile Infections Companies in the market include- Adiso Therapeutics, Deinove, Acurx Pharmaceuticals, Inc, Lumen Bioscience, Inc, Summit Therapeutics, Finch Therapeutics Group, Seres Therapeutics, Vedanta Biosciences, MGB Biopharma, Replidyne, and others. &nbsp; The Clostridium Difficile Infections market is &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/clostridium-difficile-infections-market-forecast-signals-robust-industry-growth-through-2034-delveinsight-seres-therapeutics-nestl-health-science-adiso-therapeutics-deinove-acurx-pharma_822515.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406],"tags":[],"class_list":["post-822515","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/822515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=822515"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/822515\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=822515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=822515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=822515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}